Figures & data
Table 1 Baseline Characteristics of Patients with PsO and Clinical Photography
Figure 1 Percentage of patients achieving improvements in skin and patient-reported outcomes at Week 12. All graphs show upper 95% confidence limits.
![Figure 1 Percentage of patients achieving improvements in skin and patient-reported outcomes at Week 12. All graphs show upper 95% confidence limits.](/cms/asset/917aea51-3ab7-40ae-ba49-a08c8be45503/dcci_a_12296578_f0001_c.jpg)
Figure 2 Proportion of patients showing improvements in PSSD signs and symptoms summary scores at Week 12. PSSD Signs and Symptoms summary score graphs show mean scores and upper and lower 95% confidence limits. PSSD Signs and Symptoms summary scores can range from 0 to 100. Lower scores indicate less severe disease.
![Figure 2 Proportion of patients showing improvements in PSSD signs and symptoms summary scores at Week 12. PSSD Signs and Symptoms summary score graphs show mean scores and upper and lower 95% confidence limits. PSSD Signs and Symptoms summary scores can range from 0 to 100. Lower scores indicate less severe disease.](/cms/asset/59bd3483-d5ae-4701-bd79-0e7ed371b7f3/dcci_a_12296578_f0002_c.jpg)
Figure 3 Visual treatment effects of IXE at Week 12. (A) Male aged 47 years from Italy; psoriasis for 6 years, bio-naïve, previous systemic conventional therapy, no PsA, diabetes mellitus, overweight, atherosclerosis, dyslipidemia, hypertension and liver disease, initiated IXE as per EMA label at baseline; (B) Female aged 45 from Taiwan; psoriasis for 19 years, bio-experienced, previous systemic conventional therapy, PsA and obesity, switched to IXE as per EMA label at baseline.
![Figure 3 Visual treatment effects of IXE at Week 12. (A) Male aged 47 years from Italy; psoriasis for 6 years, bio-naïve, previous systemic conventional therapy, no PsA, diabetes mellitus, overweight, atherosclerosis, dyslipidemia, hypertension and liver disease, initiated IXE as per EMA label at baseline; (B) Female aged 45 from Taiwan; psoriasis for 19 years, bio-experienced, previous systemic conventional therapy, PsA and obesity, switched to IXE as per EMA label at baseline.](/cms/asset/2153c6d9-be00-4ad2-8b45-049f42627e65/dcci_a_12296578_f0003_c.jpg)
Figure 4 Visual treatment effects of GUS at Week 12. (A) Male aged 38 from Taiwan; psoriasis for 11.4 years, bio-naïve, previous systemic conventional therapy, disease duration 12 years, no PsA, overweight, dyslipidemia and hypertension. Initiated GUS as per label at baseline. (B) Female aged 45 from Taiwan; psoriasis for 13 years, bio-experienced, previous systemic conventional therapy, disease duration 13 years, PsA. Switched to GUS as per label at baseline.
![Figure 4 Visual treatment effects of GUS at Week 12. (A) Male aged 38 from Taiwan; psoriasis for 11.4 years, bio-naïve, previous systemic conventional therapy, disease duration 12 years, no PsA, overweight, dyslipidemia and hypertension. Initiated GUS as per label at baseline. (B) Female aged 45 from Taiwan; psoriasis for 13 years, bio-experienced, previous systemic conventional therapy, disease duration 13 years, PsA. Switched to GUS as per label at baseline.](/cms/asset/5d02ffc1-3083-4950-8e46-6da70b80c4aa/dcci_a_12296578_f0004b_c.jpg)